Boceprevir is a potent orally administered inhibitor of hepatitis C virus and a strong, reversible inhibitor of CYP3A4, the primary metabolic pathway for many 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors. Thus, the aim of the present study was to investigate drug-drug interactions between atorvastatin or pravastatin and boceprevir. We conducted a single-center, open-label, fixed-sequence, one-way-crossover study with 20 healthy adult volunteers. Subjects received single-dose atorvastatin (40 mg) or pravastatin (40 mg) on day 1, followed by boceprevir (800 mg three times daily) for 7 to 10 days. Repeat single doses of atorvastatin or pravastatin were administered in the presence of steady-state boceprevir. Atorvastatin exposure increased in the presence of boceprevir, with atorvastatin area under the concentrationtime curve from time zero to infinity after single dosing (AUC inf ) increasing 2.3-fold (90% confidence interval [CI], 1.85, 2.90) and maximum observed concentration in plasma (C max ) 2.7-fold (90% CI, 1.81, 3.90). Pravastatin exposure was slightly increased in the presence of boceprevir, with pravastatin AUC inf increasing 1.63-fold (90% CI, 1.03, 2.58) and C max 1.49-fold (90% CI, 1.03, 2.14). Boceprevir exposure was generally unchanged when the drug was coadministered with atorvastatin or pravastatin. All adverse events were mild and consistent with the known safety profile of boceprevir. The observed 130% increase in AUC of atorvastatin supports the use of the lowest possible effective dose of atorvastatin when coadministered with boceprevir, without exceeding a maximum daily dose of 40 mg. The observed 60% increase in pravastatin AUC with boceprevir coadministration supports the initiation of pravastatin treatment at the recommended dose when coadministered with boceprevir, with close clinical monitoring. W orldwide, there are an estimated 130 to 170 million individuals infected with hepatitis C virus (1). Comorbidities, such as diabetes and obesity, are more common among patients with hepatitis C virus infection than in the general U.S. population, with as many as 25% of patients with hepatitis C virus infection at risk of comorbid disorders of lipid metabolism (2). Thus, patients with hepatitis C virus infection frequently receive concomitant treatments for hyperlipidemia, including the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors atorvastatin and pravastatin. Understanding potential drug interactions between hepatitis C therapies and HMG-CoA reductase inhibitors is important for optimal treatment of this patient population.
W
orldwide, there are an estimated 130 to 170 million individuals infected with hepatitis C virus (1) . Comorbidities, such as diabetes and obesity, are more common among patients with hepatitis C virus infection than in the general U.S. population, with as many as 25% of patients with hepatitis C virus infection at risk of comorbid disorders of lipid metabolism (2) . Thus, patients with hepatitis C virus infection frequently receive concomitant treatments for hyperlipidemia, including the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors atorvastatin and pravastatin. Understanding potential drug interactions between hepatitis C therapies and HMG-CoA reductase inhibitors is important for optimal treatment of this patient population.
Boceprevir is a potent, orally administered ketoamide inhibitor targeting the active site of the hepatitis C virus nonstructural protein 3 (NS3) protease, approved for the treatment of genotype 1 chronic hepatitis C virus infection in adult patients with compensated liver disease (3) (4) (5) (6) . Addition of boceprevir to a pegylated interferon (peginterferon)-ribavirin backbone is associated with significantly increased rates of sustained virologic response (SVR) (7, 8) . It is metabolized by aldoketoreductase and CYP3A4 and is a direct competitive and time-dependent inhibitor of CYP3A4/5, with inhibition constants in the low micromolar range (6) , thus having the potential for drug-drug interactions with agents that are metabolized via these common pathways (3, 5) . In vitro, boceprevir has been shown to inhibit the hepatic uptake transporter organic anion transporting polypeptide (OATP) 1B1 (50% inhibitory concentration [IC 50 ] of 18 M), but the clinical significance of this in vitro inhibition is unknown (6) . In a recent drug-drug interaction trial with digoxin, boceprevir showed only limited Pglycoprotein (P-gp) inhibitory potential at clinically relevant concentrations (9) .
Atorvastatin and pravastatin are two commonly prescribed HMG-CoA reductase inhibitors. Atorvastatin is metabolized extensively by CYP3A4, is a substrate of OATP 1B1, and may be a substrate for P-gp (10) . Concomitant use of atorvastatin and strong CYP3A4 inhibitors should be avoided because of an elevated risk of myopathy and rhabdomyolysis associated with increased plasma statin levels (11) . Because boceprevir is a strong, reversible CYP3A4 inhibitor, a drug interaction between boceprevir and atorvastatin is feasible. Pravastatin is excreted largely unchanged: it is not metabolized to a significant extent by the CYP450 system, nor is it a substrate for P-gp, but it is a substrate for the OATP 1B1 transporter. Since boceprevir is an OATP 1B1 inhibitor in vitro, drug interactions between boceprevir and pravastatin may occur at the level of OATP 1B1 (12) .
The aims of the present study were to determine the effect of steady-state boceprevir on the exposure of atorvastatin and prav-astatin and to explore the effects of atorvastatin and pravastatin on the pharmacokinetic (PK) profile of boceprevir.
(These data were presented at the 16th Annual Meeting of HEP DART, 4 to 8 December 2011, Kauai, HI.)
MATERIALS AND METHODS
This was a single-center, open-label, fixed-sequence, one-way-crossover, drug-drug interaction trial conducted with healthy adult volunteers. The study was conducted in accordance with principles of good clinical practice and was approved by the appropriate institutional review boards and regulatory agencies. All subjects provided written informed consent prior to any study-related activities.
Subjects. Healthy male and female adult volunteers aged 18 to 55 years and with body mass indices (BMI) between 18 and 32 kg/m 2 were enrolled. All subjects had clinical laboratory tests and vital signs within normal limits or that were acceptable to the investigator, and all were free of any clinically significant disease. Female subjects who were premenopausal and unsterilized were required to use a medically accepted method of contraception prior to and during the study. Subjects with hepatitis B virus surface antigen, hepatitis C virus antibodies, or HIV were excluded. Subjects with a positive drug screen or a history of alcohol or drug abuse or who smoked Ͼ10 cigarettes per day were also excluded.
Study design. For assessment of drug interactions between boceprevir and atorvastatin, healthy adult volunteers received single-dose atorvastatin (40 mg) following breakfast on day 1 of the study, followed by boceprevir (800 mg three times daily with food) on days 4 to 10 ( Fig. 1) . On day 9 of the study, all subjects also received a single dose of atorvastatin (40 mg) in addition to their morning dose of boceprevir. Blood samples for assessment of atorvastatin PKs were collected predose and at specified time points up to 48 h postdose on days 1 and 9. Samples for determination of boceprevir PKs were collected on days 8 and 9 prior to the morning dose and for up to 8 h postdose.
For assessment of drug interactions between boceprevir and pravastatin, healthy adult volunteers received a single dose of pravastatin (40 mg) following breakfast on day 1, followed by boceprevir (800 mg three times daily with food) on days 2 to 7 (Fig. 1) . On day 7, subjects also received a second single dose of pravastatin (40 mg) in addition to their morning dose of boceprevir. Blood samples for determination of pravastatin PK were collected predose and for up to 24 h postdose on days 1 and 7. Samples for determination of boceprevir PKs were collected on days 6 and 7 prior to the morning dose and for up to 8 h postdose.
In both studies, subjects who failed to comply with dosing, evaluations, or other study-related requirements were discontinued from treatment. Subjects experiencing a serious or life-threatening adverse event (AE) or who became pregnant during the study were also discontinued.
Assessments. The following primary PK parameters were evaluated: area under the concentration-time curve from time zero to the time of the last measurable sample (AUC last ), maximum observed concentration in plasma (C max ), time to maximum observed concentration in plasma (T max ), terminal phase half-life (t 1/2 ), area under the concentration-time curve from time zero to infinity after single dosing (AUC inf ), area under the concentration-time curve from time zero to 8 h (AUC 0 -8 ), apparent total body clearance (CL/F), and minimum observed concentration in plasma (C min ) (boceprevir only). All subjects also had routine laboratory tests and were monitored for the occurrence of AEs.
Assays and procedures. Assessment of the concentrations of pravastatin, atorvastatin, and the ortho-and para-hydroxylated metabolites of atorvastatin in plasma was conducted by PharmaNet Canada (Quebec, Canada). The linear range of the assay for atorvastatin was 49.80 to 49,800 pg/ml, the linear range of the assay for the ortho-hydroxylate metabolite was 49.60 to 49,600 pg/ml, and the linear range of the assay for the parahydroxylated metabolite was 50.40 to 5,040 pg/ml. The linear range of the assay for pravastatin was 0.25 to 98.50 ng/ml. The lower limits of quantitation for pravastatin, atorvastatin, ortho-hydroxylated metabolites, and para-hydroxylated metabolites were 0.25 ng/ml, 49.80 pg/ml, 49.60 pg/ ml, and 50.40 pg/ml, respectively.
Assessment of concentrations of boceprevir in plasma was conducted by PPD (Middleton, WI) using a validated high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS) method. The linear range of the assay was 4.80 to 5,200 ng/ml, and the lower limit of quantitation was 4.80 ng/ml.
Statistics. PK parameters were determined for each subject individually using noncompartmental analysis (WinNonlin, version 5.2). Descriptive statistics and statistical comparisons were carried out on the individually determined PK parameters. The linear trapezoidal rule was used to calculate the AUC. Individual AUC inf was extrapolated from the predicted concentration at the last time point with quantifiable concentrations.
For fitting to determine t 1/2 , 3 to 5 consecutive time points in the terminal phase were used, including the last time point with quantifiable concentrations but excluding C max . The specific time points varied from subject to subject but were in the range of 6 to 24 h postdose. Terminal half-life values were not reported if fewer than 3 consecutive time points in the terminal phase were available (excluding C max ) or if the regression coefficient was less than 0.9. Concentrations below the lower limit of quantitation were considered undetectable, were assigned a value of 0, and were not used to determine t 1/2 .
Target enrollment for each study was 10 subjects to ensure that at least 8 patients completed all treatments. Assuming a true geometric mean ratio (GMR) equal to 1 for AUC of atorvastatin and pravastatin when coadministered with boceprevir versus atorvastatin and pravastatin alone, a sample size of 8 conferred Ͼ99% probability that the 90% confidence interval (CI) for the GMR fell within the range of 0.50 to 2.00 for AUC. The GMR for the log-transformed AUC (atorvastatin and pravastatin plus boceprevir versus atorvastatin and pravastatin alone) and the associated 90% CI were calculated using a mixed-effect model extracting the effect due to treatment as a fixed effect and subject as a random effect.
RESULTS

Atorvastatin.
Ten healthy adult volunteers were enrolled and completed the atorvastatin drug-drug interaction study. All subjects were white, of Hispanic or Latino ethnicity, with a mean age of 34.1 years (standard deviation [SD], 8.6 years) and a mean BMI of 26.9 kg/m 2 (SD, 3.4 kg/m 2 ). Six subjects were female and 4 subjects were male.
Pharmacokinetics. Atorvastatin exposure was increased in the presence of boceprevir. The mean AUC inf s increased from 95.0 to 214 ng · h/ml upon concomitant administration of atorvastatin and boceprevir, while mean C max s increased from 10.3 to 27.7 ng/ml ( Fig. 2A and Table 1 ). The AUC inf and C max GMRs for the comparison of atorvastatin plus boceprevir versus atorvastatin alone indicate a 2.3-and 2.7-fold increase, respectively ( Table 2) . The mean T max s of atorvastatin were 2.25 h when administered alone and 4.00 h in the presence of boceprevir; mean t 1/2 values were 8.81 h and 6.73 h, respectively. Mean atorvastatin clearance decreased from 498 to 210 liters/h upon boceprevir coadministration. There was a corresponding reduction in the exposure to the ortho-hydroxy metabolite of atorvastatin with boceprevir coadministration, with a decrease in AUC last from 83.8 ng · h/ml to 35.1 ng · h/ml and C max from 7.08 ng/ml to 2.59 ng/ml. In contrast, the AUC last for the para-hydoxy metabolite was largely unchanged in the presence of boceprevir (8.09 ng · h/ml versus 9.49 ng · h/ml), while the C max was increased from 0.307 ng/ml to 0.702 ng/ml (Table 1) .
Boceprevir exposure was essentially unchanged when the drug was coadministered with atorvastatin, with GMRs of 1.04 and 0.960 for boceprevir C max and AUC 0 -8 , respectively ( Table 2 ). The CL/F, t 1/2 , and C min of boceprevir were also similar when boceprevir was administered alone or in combination with atorvastatin (CL/F, 111 liters/h versus 116 liters/h [n ϭ 10]; t 1/2 , 1.17 h versus 1.28 h [n ϭ 5]; C min , 91.3 ng/ml versus 86.6 ng/ml).
Safety. In total, 15 AEs were reported by 5 subjects; all were mild in intensity, and most occurred within 5 days of starting boceprevir treatment. Of these, 11 AEs were considered treatment related. The most frequently reported AE was mild dysgeusia, which was reported by 3 subjects (30%) receiving boceprevir (Table 3). No subjects discontinued treatment because of an AE, and there were no deaths or serious AEs during the study. There were also no clinically relevant changes in blood chemistry, hematology, blood pressure, pulse rate, oral body temperature, or electrocardiogram.
Pravastatin. Ten healthy adult subjects were enrolled, and 9 subjects completed the study. One subject was discontinued due ). Six subjects were female and 4 subjects were male.
Pharmacokinetics. Pravastatin exposure was increased slightly in the presence of boceprevir. The mean pravastatin AUC inf was increased from 99.1 to 145 ng · h/ml upon concomitant administration with boceprevir, while mean C max levels increased from 37.4 to 46.9 ng/ml ( Fig. 2B and Table 4 ). The AUC inf and C max GMRs for the comparison of pravastatin plus boceprevir versus pravastatin alone indicated 1.63-and 1.49-fold increases, respectively ( Table 5 ). The pravastatin mean elimination half-life was reduced from 4.10 to 1.76 h and the mean CL/F decreased from 673 to 343 liters/h in the presence of boceprevir ( Table 5) .
The C max , AUC, CL/F, and t 1/2 of boceprevir were generally unchanged in the presence of pravastatin compared with boceprevir alone, with GMRs between 0.9 and 1.0 for both C max and AUC 0 -8 ( Table 5 ). The CL/F and t 1/2 for boceprevir alone and in the presence of pravastatin were 117 liters/h versus 124 liters/h (n ϭ 10) and 1.23 h versus 1.12 h (n ϭ 6), respectively.
Safety.
A total of 14 AEs were reported by 7 subjects; all were considered mild, and most occurred within 5 days of initiating boceprevir. Thirteen of these AEs were considered related to boceprevir therapy, the most common of which were dysgeusia and headache, each reported by 3 patients (30%) ( Table 6) . No subjects discontinued treatment because of an AE, and there were no deaths or serious AEs during the study. There were also no clinically relevant changes in blood chemistry, hematology, blood pressure, pulse rate, oral body temperature, or electrocardiogram.
DISCUSSION
Data from the present study demonstrate that exposure to atorvastatin is increased but that there is no clinically important effect on pravastatin when these drugs are coadministered with multiple doses of boceprevir (Fig. 3) . A 2.3-fold increase in the AUC inf and a 2.7-fold increase in the C max of atorvastatin were observed following concomitant administration with boceprevir. For pravastatin, the 1.5-fold increase in C max and a 1.6-fold increase in AUC inf observed with boceprevir coadministration are not considered clinically important (13) .
Atorvastatin has low bioavailability due to extensive metabolism in the gastric mucosa and first-pass hepatic metabolism (14) . It is a substrate for P-gp and OATP 1B1 transporters and undergoes hepatic metabolism via CYP3A4 (10, 14, 15) . The increased C max and AUC of atorvastatin observed in the present study are consistent with increases in atorvastatin exposure seen with other inhibitors of CYP3A4 metabolism, such as erythromycin and itraconazole, suggesting that inhibition of CYP3A4 metabolism plays a role in the increased exposure of atorvastatin upon boceprevir coadministration (14) . However, boceprevir-mediated inhibition of the hepatic uptake transporter OATP 1B1 may also contribute to the increase in atorvastatin exposure.
Hepatic metabolism of atorvastatin by CYP3A4 produces several active metabolites, including the para-and ortho-hydroxylated products (14) . These metabolites are thought to be responsible for up to 70% of the overall HMG-CoA reductase inhibitory activity: although the half-life of atorvastatin is approximately 14 h, the half-life of HMG-CoA reductase inhibition is between 20 and 30 h (14) . In the present study, the 2.3-fold increase in atorvastatin exposure in the presence of boceprevir was paralleled by a Ͼ2-fold decrease in the AUC last of ortho-hydroxy atorvastatin, and there was essentially no change in the AUC last of the parahydroxy metabolite (8.09 ng · h/ml versus 9.49 ng · h/ml). In clinical terms, the extent to which the increased exposure of atorvastatin might be offset by reduced exposure to the active metabolites remains unclear. Mechanistically, the difference in kinetics between the para-and ortho-hydroxy metabolites may be explained by the observation that CYP2C8, in addition to CYP3A4, can mediate the formation of para-hydroxy atorvastatin but not the ortho-hydroxy metabolite (16) . Approximately 75% of the clinical activity seen with pravastatin is mediated through the parent drug, which is excreted largely unchanged; the major metabolite has substantially less activity than the parent compound (12, 14) . We observed an apparent decrease in pravastatin t 1/2 and CL/F in the presence of boceprevir. This was driven primarily by 1 to 2 subjects with high t 1/2 and CL/F values when receiving pravastatin alone, represented by a large variability in these parameters within this treatment group (Table 4 ). Since only 6 subjects receiving pravastatin alone had reportable t 1/2 and CL/F values, 1 or 2 subjects with high t 1/2 and CL/F data could influence the overall mean values, resulting in the apparent decrease in these parameters when the drugs were coadministered. The 1.6-fold increase in exposure of pravastatin seen with boceprevir coadministration cannot be explained by CYP3A4 inhibition, since pravastatin is not metabolized to a significant extent by the CYP450 enzyme system. More likely, the increase in pravastatin exposure may be due to reduced hepatic pravastatin uptake resulting from boceprevir-mediated inhibition of the OATP 1B1 transporter. Reduced hepatic pravastatin uptake may subsequently affect its excretion into the bile, elimination, and/or further intestinal absorption (14) . OATP 1B1 inhibition may also explain the increased exposure of pravastatin when coadministered with cyclosporine (7.9-fold increase in AUC and 22.8-fold increase in C max ), a known OATP 1B1 inhibitor (14, 15) . This hypothesis is also consistent with the decrease in the mean apparent clearance and t 1/2 of pravastatin with boceprevir coadministration.
A limitation of the current study is that it was conducted with healthy subjects. Although findings from healthy subjects are generally considered predictive of findings in the patient population for which the drug is intended (17), we cannot be certain that the observed drug interactions between boceprevir and atorvastatin or pravastatin are transferable to patients with hepatitis C virus infection, who may have additional comorbidities or impaired liver function. In clinical practice, boceprevir is administered together with peginterferon and ribavirin. No interactions between peginterferon or ribavirin and statins have been identified.
In conclusion, data from the present study indicate that coadministration of single-dose atorvastatin or single-dose pravastatin with multiple-dose boceprevir is safe and well tolerated in healthy volunteers. The observed 130% increase in the AUC of atorvastatin supports the use of the lowest possible effective dose of atorvastatin when coadministered with boceprevir, without exceeding a maximum daily dose of 40 mg. The observed 60% increase in the 
